Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer Journal Article
| Authors: | Wang, Y.; Ronckers, C. M.; van Leeuwen, F. E.; Moskowitz, C. S.; Leisenring, W.; Armstrong, G. T.; de Vathaire, F.; Hudson, M. M.; Kuehni, C. E.; Arnold, M. A.; Demoor-Goldschmidt, C.; Green, D. M.; Henderson, T. O.; Howell, R. M.; Ehrhardt, M. J.; Neglia, J. P.; Oeffinger, K. C.; van der Pal, H. J. H.; Robison, L. L.; Schaapveld, M.; Turcotte, L. M.; Waespe, N.; Kremer, L. C. M.; Teepen, J. C.; & The International Consortium for Pooled Studies on Subsequent Malignancies after Childhood and Adolescent Cancer |
| Article Title: | Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer |
| Abstract: | Anthracycline-based chemotherapy is associated with increased subsequent breast cancer (SBC) risk in female childhood cancer survivors, but the current evidence is insufficient to support early breast cancer screening recommendations for survivors treated with anthracyclines. In this study, we pooled individual patient data of 17,903 survivors from six well-established studies, of whom 782 (4.4%) developed a SBC, and analyzed dose-dependent effects of individual anthracycline agents on developing SBC and interactions with chest radiotherapy. A dose-dependent increased SBC risk was seen for doxorubicin (hazard ratio (HR) per 100 mg m−2: 1.24, 95% confidence interval (CI): 1.18–1.31), with more than twofold increased risk for survivors treated with ≥200 mg m−2 cumulative doxorubicin dose versus no doxorubicin (HR: 2.50 for 200–299 mg m−2, HR: 2.33 for 300–399 mg m−2 and HR: 2.78 for ≥400 mg m−2). For daunorubicin, the associations were not statistically significant. Epirubicin was associated with increased SBC risk (yes/no, HR: 3.25, 95% CI: 1.59–6.63). For patients treated with or without chest irradiation, HRs per 100 mg m−2 of doxorubicin were 1.11 (95% CI: 1.02–1.21) and 1.26 (95% CI: 1.17–1.36), respectively. Our findings support that early initiation of SBC surveillance may be reasonable for survivors who received ≥200 mg m−2 cumulative doxorubicin dose and should be considered in SBC surveillance guidelines for survivors and future treatment protocols. © 2023, The Author(s). |
| Keywords: | adolescent; adult; cancer chemotherapy; cancer survival; child; controlled study; major clinical study; doxorubicin; cancer risk; cancer radiotherapy; cancer diagnosis; breast cancer; cohort analysis; risk factor; childhood cancer; risk assessment; europe; daunorubicin; epirubicin; cancer epidemiology; idarubicin; anthracycline; north america; cumulative incidence; demographics; childhood cancer survivor; invasive breast cancer; human; female; article; ductal breast carcinoma in situ |
| Journal Title: | Nature Medicine |
| Volume: | 29 |
| Issue: | 9 |
| ISSN: | 1078-8956 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2023-09-01 |
| Start Page: | 2268 |
| End Page: | 2277 |
| Language: | English |
| DOI: | 10.1038/s41591-023-02514-1 |
| PUBMED: | 37696934 |
| PROVIDER: | scopus |
| PMCID: | PMC10504074 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
